The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.


Bexell lab

For a complete list of publications, please visit our Lund University Research Portal page (linked on the right hand side).

Selected publications

Mañas A, Aaltonen K, Andersson N, Hansson K, Adamska A, Seger A, Yasui H, Van den Bos H, Radke K, Esfandyari J, Bhave M, Karlsson J, Spierings D, Foijer F, Gisselsson D, Bexell D. Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance. Sci Adv. 2022 Oct 28;8(43):eabq4617. Link to article

Radke K, Hansson K, Sjölund J, Wolska M, Karlsson J, Esfandyari J, Pietras K, Aaltonen K, Gisselsson D, Bexell D (2021). Anti-tumor effects of rigosertib in high-risk neuroblastoma. Translational Oncology, Volume 14, Issue 8, August 2021, 101149. Link to article

Hansson K, Radke K, Aaltonen K, Saarela J, Manas A, Sjölund J, Smith EM, Pietras K, Påhlman S, Wennerberg K, Gisselsson D, Bexell D. (2020). Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. Science Transl Med. 2020 Sep 23;12(562):eaba4434 Link to article

Mohlin S*, Hansson K*, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D. (2019). Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma. EMBO Mol Med. 2019 Aug;11(8):e10058.  *equal contribution Link to article

Braekeveldt N*, von Stedingk K*, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, Noguera R, Karlsson J, Koster J, Martinsson T, Gisselsson D, Påhlman S, Bexell D. (2018). Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Res. 2018 Aug 28. *equal contribution Link to article

Karlsson J, Valind A, Holmquist Mengelbier L, Bredin S, Cornmark L, Jansson C, Wali A, Staaf J, Viklund B, Øra I, Börjesson A, Backman T, Braekeveldt N, Sandstedt B, Pal N, Isaksson A, Lackner BG, Jonson T, Bexell D, Gisselsson D. (2018). Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer. Nature Genet. 2018 Jul;50(7):944-950. Link to article

Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, Erjefält J, Berbegall AP, Börjesson A, Backman T, Ora I, Navarro S, Noguera R, Gisselsson D, Påhlman S, Bexell D. (2016). Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett. 2016 Jun 1;375(2):384-9 Link to article

Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D. (2015). Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2015 Mar 1;136(5):E252-61. Link to article